Pharmaceutical

Ocuphire and Opus Genetics merge to develop IRD gene therapy

Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs).

Oct 24, 2024 - 04:00
Ocuphire and Opus Genetics merge to develop IRD gene therapy
Ocuphire Pharma has announced the acquisition of Opus Genetics to develop gene therapies for inherited retinal diseases (IRDs).
Read the original article

Tags:

Previous Article

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

Next Article

FDA approves Alvotech and Teva’s SELARSDI for new indications

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Mammograms are less effective for women with dense breast tissue. Medical experts disagree on what to do about it

Mammograms are less effective for women with dense brea...

Jan 24, 2024

Here’s why obesity grew so quickly worldwide, and where that’s starting to change

Here’s why obesity grew so quickly worldwide, and where...

Jun 8, 2023

STAT+: Medicare’s advisory committee isn’t sold on big pay raises for doctors

STAT+: Medicare’s advisory committee isn’t sold on big ...

Dec 9, 2023